Beta Bionics, Inc. BBNX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 52.54% | -- | -- | -- | 97.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.54% | -- | -- | -- | 97.91% |
| Cost of Revenue | 38.02% | -- | -- | -- | 101.37% |
| Gross Profit | 64.94% | -- | -- | -- | 95.05% |
| SG&A Expenses | 53.82% | -- | -- | -- | 85.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.74% | -- | -- | -- | 80.64% |
| Operating Income | -32.77% | -- | -- | -- | -62.89% |
| Income Before Tax | 0.54% | -- | -- | -- | -34.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.54% | -- | -- | -- | -34.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.54% | -- | -- | -- | -34.77% |
| EBIT | -32.77% | -- | -- | -- | -62.89% |
| EBITDA | -31.78% | -- | -- | -- | -64.83% |
| EPS Basic | 70.03% | -- | -- | -- | 40.72% |
| Normalized Basic EPS | 70.03% | -- | -- | -- | 40.72% |
| EPS Diluted | 70.03% | -- | -- | -- | 40.72% |
| Normalized Diluted EPS | 70.03% | -- | -- | -- | 40.72% |
| Average Basic Shares Outstanding | 102.23% | -- | -- | -- | 276.58% |
| Average Diluted Shares Outstanding | 102.23% | -- | -- | -- | 276.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |